You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Recurrent Breast Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Toxicities of Salvage Treatment in Locoregionally Recurrent

Not yet recruiting
  • Breast Cancer
  • Salvage treatment (surgery and/or radiation therapy)
  • Seoul, Korea, Republic of
    Samsung Medical Center
Jul 5, 2023

Breast Cancer, Recurrent Trial in Meldola (Partial breast re-irradiation)

Not yet recruiting
  • Breast Cancer
  • Recurrent
  • Partial breast re-irradiation
  • Meldola, Forlì Cesena, Italy
    UO Radioterapia, IRST IRCCS
Mar 6, 2023

Breast Cancer Trial in Chikusa-ku, Chuo-ku (KHK2375, Exemestane)

Completed
  • Breast Cancer
  • Chikusa-ku, Aichi, Japan
  • +2 more
Jun 15, 2022

Breast Cancer Trial in Beijing (Drug: 68Ga-P16-093)

Recruiting
  • Breast Cancer
  • Drug: 68Ga-P16-093
  • Beijing, China
    Peking Union Medical College Hospital
Nov 14, 2022

Breast Cancer Stage IIB Trial in Philadelphia (Hydroxychloroquine, Everolimus)

Recruiting
  • Breast Cancer Stage IIB
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jun 8, 2022

Breast Cancer Trial in United Kingdom (Hydrogen Peroxide)

Recruiting
  • Breast Cancer
  • Hydrogen Peroxide
  • Lucknow, Uttar Pradesh, India
  • +7 more
Sep 21, 2022

Breast Cancer Trial (SHR-A1811, Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Apr 3, 2023

Metastatic Breast Cancer Trial (SKB264, Eribulin, Capecitabine)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Oct 7, 2023

Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer Trial in Shanghai (BL-B01D1, SI-B003)

Not yet recruiting
  • Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Sep 12, 2023

HER2-PositiveRecurrent or Metastatic Breast Cancer Trial (SHR-A1811 Injection, SHR-A1811 Injection ; Pertuzumab Injection,

Not yet recruiting
  • HER2-PositiveRecurrent or Metastatic Breast Cancer
  • SHR-A1811 Injection
  • +2 more
  • (no location specified)
Sep 21, 2023

Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications, Progesterone Receptor-positive Breast Cancer Trial in

Active, not recruiting
  • Estrogen Receptor-positive Breast Cancer
  • +9 more
  • Boston, Massachusetts
  • +1 more
Sep 9, 2022

Breast Cancer Female, Breast Cancer Recurrent Trial in Drammen (18F-FDG PET/CT)

Recruiting
  • Breast Cancer Female
  • Breast Cancer Recurrent
  • 18F-FDG PET/CT
  • Drammen, Norway
    Drammen Hospital - Vestre Viken HF
Feb 17, 2023

Breast Tumors Trial in Hangzhou (Sindilimab, Nab-paclitaxel, Lenvatinib)

Not yet recruiting
  • Breast Neoplasms
  • Hangzhou, Zhejiang, China
    ZhejiangCH
Nov 17, 2023

Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, NSCLC Trial in United States (LYL797)

Recruiting
  • Triple Negative Breast Cancer
  • +14 more
  • LYL797
  • Scottsdale, Arizona
  • +10 more
Jan 30, 2023

PET/CT Parameters and Tumor Markers in Recurrent Breast Cancer

Not yet recruiting
  • Breast Cancer
  • PET/CT
  • (no location specified)
Sep 30, 2021

Advanced or Recurrent Breast Cancer Trial in Japan (Entinostat, Entinostat(Placebo), Exemestane)

Completed
  • Advanced or Recurrent Breast Cancer
  • Nagoya, Aichi, Japan
  • +27 more
Jun 15, 2022

First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer Trial (KN026, HB1801, Pertuzumab)

Not yet recruiting
  • First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
  • (no location specified)
Apr 20, 2023

HER2-positive Breast Cancer Trial in Chengdu (Recombinant anti-HER2 humanized mAb conjugate for injection.R&D code: B003.)

Active, not recruiting
  • HER2-positive Breast Cancer
  • Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Jan 30, 2023

Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Boston,

Active, not recruiting
  • Estrogen Receptor-positive Breast Cancer
  • +5 more
  • PI3K inhibitor BYL719
  • +3 more
  • Boston, Massachusetts
  • +1 more
Oct 14, 2022

Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer Trial in London (Palbociclib, Avelumab)

Recruiting
  • Triple Negative Breast Cancer
  • +5 more
  • Manchester, Greater Manchester, United Kingdom
  • +6 more
Jan 5, 2023

Metastatic Castration-resistant Prostate Cancer, Recurrent Epithelial Ovarian Cancer, Breast Cancer Trial (AsiDNA, Olaparib)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • +2 more
  • (no location specified)
Jan 17, 2023

Edema, Erythema, Estrogen Receptor Negative Trial in Houston (Laboratory Biomarker Analysis, Pembrolizumab)

Active, not recruiting
  • Edema
  • +8 more
  • Laboratory Biomarker Analysis
  • Pembrolizumab
  • Houston, Texas
    M D Anderson Cancer Center
Jan 23, 2023

Omitting Axillary Surgery in Breast Cancer Isolated Chest Wall

Recruiting
  • Breast Cancer
  • Recurrent Disease
  • axillary surgery
  • Singapore, Singapore
    KK Women's and Children's Hospital
Oct 12, 2023

Triple Negative Breast Cancer Trial in Beijing (Eribulin Mesylate, Lobaplatin)

Recruiting
  • Triple Negative Breast Cancer
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Sep 15, 2022

LYNPARZA Breast Cancer in Adjuvant Setting Japan Post-Marketing

Not yet recruiting
  • Breast Cancer
    • (no location specified)
    Jan 9, 2023